A Multicenter, Randomized, Double-Blinded, Monotherapy-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of the Acarbose and Metformin in Loose-Dose Combination Compared to Metformin Monotherapy in Subjects WithType 2 Diabetic Mellitus (T2DM) That is Inadequately Controlled by Metformin Monotherapy
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Acarbose/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Bayer
- 18 Dec 2017 Planned End Date changed from 14 Feb 2019 to 17 Jun 2019.
- 18 Dec 2017 Planned primary completion date changed from 14 Feb 2019 to 17 Jun 2019.
- 18 Dec 2017 Planned initiation date changed from 28 Nov 2017 to 28 Mar 2018.